"id:ID","uuid","studyTitle","studyRationale","studyAcronym","studyVersion","id"
"821","13810d84-e767-48b8-a0cc-e7c400d522ec","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","H2Q-MC-LZZT","2","StudyVersion_1"
